Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DoorDash Inc (DASH) vs Quest Diagnostics Inc (DGX) Price & Performance

DoorDash IncTrade
Quest Diagnostics IncTrade

Price performance (Past 24H)

Key statistics

DoorDash Inc vs Quest Diagnostics Inc — how do they compare? DoorDash Inc trades at $212.37 (market cap $90.93B), while Quest Diagnostics Inc trades at $237.51 (market cap $26.23B). The key difference: DoorDash Inc is far larger — about 3.5× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while DoorDash Inc pays none. Which is the better fit depends on your goals.

DASHDGX
Market Cap
$90.93B$26.23B
Sector
Consumer CyclicalHealth
52-Week High
$281.74$238.50
52-Week Low
$146.60$173.49
Enterprise Value
$88.89B$31.99B
Dividend Yield
1.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DoorDash Inc

DoorDash (DASH) trades at $216.26, up 1.41% with strong technical momentum above key support levels. The company demonstrates robust revenue growth, with Q2 2026 revenue up 36% YoY to $4.45B, though earnings missed estimates due to higher R&D costs. Analyst sentiment remains overwhelmingly positive with 75.68% buy ratings and a $247.41 consensus price target, representing 14.4% upside potential from current levels.

DoorDash's expansion into grocery, retail, and international markets supports growth, but elevated valuation multiples (P/E 113.23) and intense competition present risks. The stock's technical strength and fundamental growth trajectory suggest continued upside, though investors should monitor execution on profitability targets and competitive pressures in the delivery space.

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $238.35, down slightly by 0.06% today, but maintains a bullish technical trend with strong earnings momentum, having beaten EPS estimates in the last three quarters. Revenue grew to $11.04 billion in 2025, with net income reaching $992 million, and the company raised its 2026 outlook amid surging testing demand. Analyst consensus is a Buy with a $249.50 price target, though valuation multiples like a P/E of 25.3 suggest premium pricing.

The outlook for DGX is positive due to robust demand for diagnostic services, AI integration, and partnerships driving growth, but risks include margin pressure from lower-margin deals and high debt levels. Investors may find opportunity in sustained earnings beats and dividend payouts, yet should monitor competitive and cost pressures that could affect profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About DoorDash Inc

Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).

Read more on DASH

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX